CN1649551A - 药物释放型血管内支架和治疗再狭窄的方法 - Google Patents

药物释放型血管内支架和治疗再狭窄的方法 Download PDF

Info

Publication number
CN1649551A
CN1649551A CNA038093111A CN03809311A CN1649551A CN 1649551 A CN1649551 A CN 1649551A CN A038093111 A CNA038093111 A CN A038093111A CN 03809311 A CN03809311 A CN 03809311A CN 1649551 A CN1649551 A CN 1649551A
Authority
CN
China
Prior art keywords
coating
support
restenosis
polymer
described support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA038093111A
Other languages
English (en)
Other versions
CN1649551B (zh
Inventor
J·E·舒尔泽
R·E·贝茨
D·R·萨维吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosensors International Group Ltd
Original Assignee
Sun Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29268785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1649551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Biomedical Ltd filed Critical Sun Biomedical Ltd
Publication of CN1649551A publication Critical patent/CN1649551A/zh
Application granted granted Critical
Publication of CN1649551B publication Critical patent/CN1649551B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/072Encapsulated stents, e.g. wire or whole stent embedded in lining
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/91533Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • A61F2002/91575Adjacent bands being connected to each other connected peak to trough
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/0054V-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/08Coatings comprising two or more layers

Abstract

本发明公开了一种血管内支架和抑制血管损伤后的再狭窄的方法。所述支架具有一个可扩张的、相互连接的细丝体和在支架体细丝上形成的可释放药物的涂层,当支架被放入血管损伤部位时,支架扩张,使支架涂层与血管损伤部位相接触。涂层可释放抑制再狭窄量的大环三烯化合物,该化合物在碳位40有一个烷基取代基。当该支架用于治疗血管损伤时,可以很好的防止临床再狭窄,即使血管损伤程度涉及血管过度拉伸在直径上超过30%也可以做到。本发明还公开了具有药物释放涂层的支架,所述涂层由(i)10-60%(重量比)的聚-dl-丙交酯聚合物底材和(ii)40-90%(重量比)的抗再狭窄化合物组成;该支架还具有厚度为1-5微米的聚合物底层。

Description

药物释放型血管内支架和治疗再狭窄的方法
发明领域:
本发明涉及药物释放型血管内支架和治疗再狭窄的方法。
发明背景
支架是一种血管内植入物,通常为管状,一般具有网状、相互连接的金属丝管状结构,其可以扩张,可以永久地置入血管中以对血管提供机械支撑并在血管成形术过程中或术后保持或重建血流通道。支架的支撑结构被设计为能防止由血管成形术导致的变弱和损伤的血管的早期塌陷。已证实支架的置入可在受损血管壁愈合过程的数月期间内防止血管的负性重构和痉挛。
在愈合的过程中,由血管成形术和支架置入损伤所引起的炎症经常导致平滑肌细胞在支架内增殖和再生长,因而使部分血流通道闭塞,由此降低或消除了血管成形术/支架手术的有益效果。这个过程被称为再狭窄。由于支架表面有形成血栓的特性,即使用生物相容性材料制成的支架,在新置入的支架内也可产生血凝块。
由于目前的做法是在血管成形术过程中在血液循环中注入强抗血小板药,所以在手术期间和手术之后短期内不会有大的血凝块形成,但总会有一些血栓存在,至少可以在显微镜下在支架表面观察到,有人认为它通过在支架表面建立生物相容性基质而在再狭窄的早期起重要作用,平滑肌细胞随后在其上附着并增殖。
含有生物活性剂的支架涂层是已知的,它被设计用来减少或消除血栓形成或再狭窄。在支架置入前,所述生物活性剂分散或溶解在附着于支架丝表面的生物耐久性或可生物降解的聚合物基质中。支架置入后,生物活性剂从聚合物基质向外扩散,优选扩散进入周围组织,扩散至少维持4周,在有些情况下可以长达一年或更长,理想的是与再狭窄、平滑肌细胞增殖、血栓形成或这几种情况的组合的时间进程相匹配。
若聚合物是可生物降解的,除通过扩散过程释放药物外,生物活性剂还可以在聚合物被降解或溶解时释放,使周围组织更易得到该生物活性剂。其外表面或甚至整个聚合材料都是多孔的可生物降解的支架和生物耐久性支架是已知的。例如,PCT公布号WO99/07308(与本申请属于同一申请人)公开了这种支架,该专利申请引入本文作为参考。当可生物降解聚合物被用作递送药物的涂层时,许多专利描述了多孔性可帮助组织向内生长,使聚合物的降解更可预见,或调控或提高药物释放速率,例如US专利:6,099,562、5,873,904、5,342,348、5,873,904、5,707,385、5,824,048、5,527,337、5,306,286和6,013,853中所述。
肝素及其它抗血小板或抗血栓溶解表面涂层是已知的,它们化学结合在支架的表面以减少血栓形成。已知肝素化的表面可以干扰人的凝血级联反应,防止血小板(凝血酶的前体)在支架表面的附着。表面含肝素并且涂层内储有活性剂的支架已有记载(参见例如US专利6,231,600和5,288,711)。
有许多活性剂可以抑制平滑肌细胞的增殖,从而抑制再狭窄,已有人提出将这些活性剂用于从血管内支架释放。例如,美国专利6,159,488描述了使用喹唑啉酮衍生物;美国专利6,171,609描述了使用Taxol;美国专利5,176,98描述了使用紫杉醇,它是一种被认为是药物Taxol中的活性成分的细胞毒性剂。在美国专利5,873,904中提到了金属银。在美国专利5,733,327中公开了曲尼司特,它是一种被认为具有抗炎特性的膜稳定剂。
最近,雷帕霉素,一种据报道可以抑制平滑肌细胞和内皮细胞生长的免疫抑制剂,当从支架上的聚合物涂层给药时,被证实具有改善的抗再狭窄的效力。参见例如美国专利5,288,711和6,153,252。此外,PCT公布号WO97/35575中提出了用大环三烯免疫抑制化合物依维莫司(everolimus)和相关化合物通过全身给药来治疗再狭窄。
理想的是,被选择用来通过从支架上释放药物来抑制再狭窄的化合物应具有以下三方面特性:
1、由于支架的轮廓要小,即聚合物基质薄,要求从薄的聚合物涂层释放出的化合物有足够的活性以产生持续治疗剂量最少4-8周。
2、化合物在低剂量的条件下能有效抑制平滑肌细胞增殖。
3、血管腔内表面的内皮细胞在血管成形术和/或置入支架过程中一般会被损伤,化合物应允许内皮细胞在血管腔内再生长,提供血管内环境稳定的回归,促进血管壁和通过血管的血流的正常和重要的相互作用。
发明概述
一方面,本发明包括一种用于置入血管损伤部位以抑制此部位再狭窄的血管内支架。支架由一个或多个细丝所形成的结构件或结构体构成,并且在支架体细丝上带有厚度为3-15微米的可生物降解的药物释放涂层,所述涂层由(i)20-60%(重量比)的聚-dl-丙交酯聚合物底材和40-80%(重量比)的抗再狭窄化合物组成。聚合物底层厚度为1-5微米,位于支架体细丝和涂层之间,起稳定支架细丝上的涂层的作用。支架可以从收缩状态扩张,在收缩状态下,可以将支架通过导管传送到血管损伤部位,在扩张状态时,支架涂层与血管的损伤部位相接触。支架被放入血管损伤部位后,支架涂层能够在至少4周的时间内有效释放再狭窄抑制量的化合物。
在各种示例性的实施方案中,抗再狭窄化合物是一种大环三烯免疫抑制化合物,支架体是金属丝结构,紧附金属丝的底层由聚对亚苯基二甲基聚合物形成,其厚度为0.5-5微米;涂层的厚度为2-10微米。化合物在涂层中的含量可以为50-75%(重量比)。
示例性的大环三烯免疫抑制化合物有以下结构:
其中,(i)当R’是H(R’替代了28位O上的H)时,R是H或CH2-X-OH,并且X是直链或支链的含1-7个碳原子的烷基,或者(ii)R’和R中至少有一个为以下形式:
Figure A0380931100081
m是1-3的整数,R1和R2分别是氢或具有1-3个碳原子的烷基,或者R1和R2与它们所连接的氮原子一起形成具有4个碳原子的饱和杂环。在一个示例性的化合物依维莫司中,R’是H,X是-CH2
根据本发明的另一方面,上述支架被用于抑制血管损伤部位再狭窄的方法中。在该方法中,支架被导入血管损伤部位,然后扩张使支架涂层与血管损伤部位相接触。涂层可在至少4周的时间内有效地释放再狭窄抑制量的化合物。
在另一方面,本发明包括一种血管内支架,该支架用于放入血管损伤部位以抑制该部位的再狭窄。该支架由一个或多个细丝所形成的结构件或结构体构成,并且在支架体细丝上带有厚度为3-25微米的可释放药物的涂层,所述涂层由(i)20-70%重量比的聚合物底材和(ii)30-80%重量比的大环三烯免疫抑制化合物组成,其分子结构如下:
其中R是CH2-X-OH,X是含1-7个碳原子的直链基团。
支架可以从收缩状态扩张,在收缩状态下,可以将支架通过导管传送到血管损伤部位,在扩张状态时,支架涂层与血管的损伤部位相接触。支架被放入血管损伤部位后,支架涂层能够在至少4周的时间内有效释放再狭窄抑制量的化合物。
在多种示例性的实施方案中,R是CH2-X-OH,X是-CH2-,支架体是一个金属丝结构,涂层中的聚合物底材是聚甲基丙烯酸甲酯、乙烯乙烯醇共聚物或聚-dl-丙交酯聚合物。
在一个示例性的实施方案中,涂层中的聚合物底材是由可生物降解的聚-dl-丙交酯形成的,其厚度为3-20微米;涂层中所含化合物的初始浓度为涂层总重量的20-70%。特别是,当涂层中化合物的含量大于40%(重量)时,所述支架还可以在支架体细丝和聚-dl-丙交酯涂层底材之间有一层厚度为1-5微米的聚对亚苯基二甲基聚合物底层。
或者,支架体和涂层底材均可由可生物降解聚合物形成,例如由聚-l-丙交酯或聚-dl-丙交酯形成支架体细丝,由聚-dl-丙交酯形成涂层底材。
当支架被放入指定位置时,在扩张状态下,支架涂层与通过支架的血流相接触。在该实施方案中,涂层可进一步含有生物活性剂如抗血小板剂、纤维蛋白溶解剂或可溶结晶形式的溶栓剂。抗血小板剂、纤维蛋白溶解剂或溶栓剂的实例是肝素、阿司匹林、水蛭素、噻氯匹定、eptifibatide、尿激酶、链激酶、组织纤溶酶原激活物(TPA)或它们的混合物。
再一方面,本发明提供了一种通过放入被设计用来在延长的时间内释放大环三烯免疫抑制化合物的血管内支架来治疗血管损伤部位再狭窄的改进的方法。该改进包括使用大环三烯免疫抑制化合物,化合物的结构式为:
R是CH2-X-OH,X是含1-7个碳原子的直链烷基。在一个示例性的化合物中,X是-CH2-。
支架组成的各种示例性实施方案如上所述。
本发明还公开了一种把含药的聚合物涂层涂到支架体细丝上的新方法。该方法使用自动控制器调整聚合物或含药聚合物溶液流到支架体细丝上,以获得多种支架涂层特性中的一种,包括在支架体细丝一面或多面上的涂层厚度是均匀的;在支架体外(或内)表面的涂层厚度比另一面的厚;内和外涂层含不同的药物;和/或在支架体上涂层厚度有坡度或不连续涂层。
通过以下结合附图对本发明的详细描述,本发明的这些以及其它的目的和特点将更加清楚。
附图概述
图1和图2显示了按照本发明的一个实施方案形成的具有金属丝体的血管内支架,图1是支架的收缩状态;图2是支架的扩张状态。
图3是图1的支架中涂层的金属丝的横断面放大图。
图4是一个带有涂层的可降解聚合物支架的横断面放大图。
图5A和5B是适用于生产本发明的涂层支架的聚合物涂层方法的示意图。
图6是按照本发明构建的可生物降解聚合物支架被安装在用于送至血管部位的导管上的示意图。
图7A和7B是从本发明的支架释放依维莫司的函数图。
图8是本发明支架置入血管部位后的横断面图。
图9A-9C是置入裸金属支架28天后的血管组织学切片。
图10A-10C是置入含聚合物涂层的金属丝支架28天后的血管组织学切片。
图11A-11C和12A-12C是置入含依维莫司的聚合物涂层金属丝支架28天后的血管组织学切片。
图13是一个放大的血管组织学切片,其中可见图11A-11C所用支架的细丝,该细丝上长满新的组织,形成愈合的血管壁。
图14是各种支架、包括按照本发明构建的支架置入后28天时,狭窄的面积与损伤度的函数图。
图15显示一个校正函数图,Y轴为损伤度,X轴为支架置入时B/A(球囊/动脉)的比率。
发明详述
第一部分、血管内支架
图1和图2分别显示了收缩和扩张状态的按照本发明构建的支架20。支架包括一个结构件或结构体22和用来包含和释放抗再狭窄化合物的外涂层,以下将参照图3和图4做进一步描述。
A、 支架体
在所示的实施方案中,支架体是由多个通过细丝相连的管状件,如件24和26组成。每个件具有可扩张的Z型锯齿或正弦波结构。各件体通过轴向连接件,例如将相邻部件的波峰和波谷相连的连接件28、30连接。可以理解,此结构使支架可以从收缩状态(如图1所示)扩张到扩张状态(如图2所示),而支架的长度不变或有少许改变。同时,相邻管状件的峰谷之间相对较少的连接使得支架可以弯曲。此特性对于支架在导管中或导管上以收缩状态被导入血管部位特别重要。支架有一个0.5-2mm的典型收缩状态直径(图1),更优选0.71-1.65mm,长度为5-100mm。在支架的扩张状态(见图2),支架的直径至少是它收缩状态的2倍,甚至可达到8-9倍。因此,一个收缩态直径在0.7-1.5mm的支架可放射状地扩张到直径为2-8mm或更大的选定扩张状态。
具有这样的由相连的、可扩张的管状件构成的支架体的支架是已知的,如PCT公布号WO99/07308所述,该专利申请与本申请属于同一申请人,并且引入本文作为参考。其它的例子记载于美国专利6,190,406、6,042,606、5,860,999、6,129,755或5,902,317中,这些专利引入本文作为参考。或者,支架的结构件也可能是连续的螺旋状丝带结构,即,支架体是由单一的连续的丝带样螺旋构成。支架体的基本要求是在放置于血管损伤部位时可以扩张,并且在其外表面能涂覆含药物的涂层,能将涂层中所含的药物输送到血管靶点内层的血管壁(如:组织的中膜、外膜和内皮层)内。优选地,支架体还具有网状或开放结构,允许内皮细胞穿过支架从外向内生长。
B、 支架涂层
根据本发明的一个重要特征,支架丝上涂有可释放药物的涂层,该涂层由聚合物基质和分布在基质内的抗再狭窄化合物(活性化合物)组成,用于在至少数周、一般是4-8周,有时持续2-3个月或更长的时期内从支架上释放出药物。
图3以放大的断面图的方式显示了具有涂层32的支架丝24,所述涂层完全覆盖了细丝的所有面,即顶部(形成支架体外表面的细丝侧面)、底部(形成支架体内表面的细丝侧面)和相对的细丝侧面。正如以下将要进一步讨论的,涂层的厚度通常为3-30微米,该厚度取决于构成涂层的聚合物基质材料的性质和聚合物基质与活性化合物的相对量。理想的是,涂层尽可能的薄,如15微米或更小,以使支架在血管损伤部位的轮廓最小。
上(外)表面涂层的厚度也应该相对均匀,以促进释放的药物在靶点的均匀分布。在支架丝上产生相对均匀厚度的涂层的方法将在第二部分讨论。
图3显示了在支架丝和涂层间有一层聚合物底层34。底层的目的是帮助支架体细丝与涂层间的粘合,即稳定细丝上的涂层。以下会看到,此功能在形成涂层的聚合物底材中含有高百分比的抗再狭窄化合物(如:35-80%重量的化合物)时特别有价值。一种底层聚合物的例子是聚对亚苯基二甲基,其用以连接由可生物降解的聚-dl-丙交酯形成的聚合物底材。其它适用的聚合物底层为乙烯乙烯醇共聚物(EVOH)、paryLASTTM、聚对亚苯基二甲基、聚硅氧烷、TEFLONTM和其它含氟聚合物,它们可以通过等离子涂覆、其它涂覆或沉淀工艺沉积在金属支架表面。底层厚度一般为1-5微米。
形成底材的聚合物可以是任何生物相容性聚合物材料,其中所包含的化合物可以通过扩散和/或通过聚合物基质的降解而释放。两种公知的不可降解的用于涂层底材的聚合物是聚甲基丙烯酸甲酯、乙烯乙烯醇共聚物。制备适用于支架体的这些聚合物的方法描述在US2001/0027340A1和WO00/145763中,这两篇申请引入本文作为参考。通常,加入聚合物的药物限量是约20-40%重量。
可生物降解的聚合物,特别是聚-dl-丙交酯,也适合作为涂层底材材料。在本发明中的一个的实施方案中,涂层是可生物降解的聚-dl-丙交酯聚合物底材,即聚-dl-乳酸聚合物,其可容高达80%(干重)的活性化合物分散在聚合物底材内。更一般的,涂层含35-80%干重的活性化合物和20-65%干重的聚合物。示例性的涂层含25-50%干重的聚合物基质和50-75%重量的活性化合物。关于用于沉淀于支架丝上的聚合物和药物的合成的详细说明见第二部分。
有多种抗再狭窄化合物可以用于该实施方案,包括抗增殖剂如TAXOL、反义化合物、阿霉素和最特别的大环三烯免疫抑制化合物,其具有以下所示的通式。后一类化合物和它们的合成记载于在美国专利4,650,803、5,288,711、5,516,781、5,665,772和6,153,252;PCT公布号WO97/35575,美国专利申请号6273913B1、60/176086、20000212/17和2001002935/A1,所有这些专利和专利申请在此引为参考。示例性的大环三烯免疫抑制化合物具有如下结构:
其中(i)当R’是H(R’替代了28位O上的H)时,R是H或CH2-X-OH,并且X是直链或支链的含1-7个碳原子的烷基,或者(ii)R’和R中至少有一个为以下形式:
Figure A0380931100132
m是1-3的整数,R1和R2分别是氢或具有1-3个碳原子的烷基,或者R1和R2与它们所连接的氮原子一起形成具有4个碳原子的饱和杂环。在一个示例性的化合物依维莫司中,R’是H,X是-CH2
一种优选的涂层由25-50%重量的聚-dl-丙交酯聚合物底材和50-75%重量的大环三烯免疫抑制化合物形成,涂层厚度为3-15微米。底层是聚对亚苯基二甲基,厚度为1-5微米。该实施方案中,化合物的含量相当于15μg药物/mm支架长。
在另一个实施方案中,涂层由15-35%重量的可降解或不可降解的聚合物底材和65-85%重量的大环三烯化合物形成。涂层厚度优选为10-30微米,支架还可以含1-5微米的聚合物底层,如聚对亚苯基二甲基底层。在该实施方案中,化合物的含量相当于约15μg药物/mm支架长。活性化合物具有如下结构:
Figure A0380931100141
其中R是CH2-X-OH,X是含1-7个碳原子的直链烷基。优选的化合物是依维莫司,其中X=-CH2。X是2、3、4、5、6或7个碳原子的烷基的化合物,无论是单独使用还是以任何组合使用,以及前述化合物、包括依维莫司的乙酸酯的应用,也适用于本发明。
涂层还可以含有第二种可以将血液相关事件例如可能由原血管损伤或支架的存在刺激形成的凝血降至最小或改善血管损伤的愈合的生物活性剂。第二种活性剂的例子包括抗血小板剂、纤维蛋白溶解剂或可溶结晶形式的溶栓剂,或可刺激内皮细胞愈合和控制平滑肌细胞生长的NO供体。抗血小板剂、纤维蛋白溶解剂或溶栓剂的实例是肝素、阿司匹林、水蛭素、噻氯匹定、eptifibatide、尿激酶、链激酶、组织纤溶酶原激活物(TPA)或它们的混合物。第二活性剂在支架涂层中的含量由需要该活性剂提供治疗益处的时期的长短来决定。通常,活性剂在血管损伤和支架置入后的最初几天发挥作用,虽然对于一些活性剂而言,要求更长的释放期。
可以根据已知方法将第二种活性剂包含在涂层配方中涂到支架细丝上。
C、 可生物降解支架
在另一个实施方案中,支架体和聚合物涂层均由可生物降解聚合物构成,经一定时间支架被完全吸收。支架优选是一个可扩张的螺旋支架,它具有由螺旋带状细丝形成的支架体(无图示)。在美国专利4,990,155中记载了用于植入血管的自扩张螺旋支架,在此引为参考。
螺旋支架可以用预成形的支架来制备,预成形支架的最终扩张直径略大于拟用此螺旋支架治疗的血管内腔尺寸(对于冠状动脉常见的是3.5mm外径(OD)±1mm)。通常,支架可以通过如下方式制备:铸模扩张状态下的支架,再以支架的长轴为轴拧支架使其处于收缩状态或径向压支架让其处于收缩状态,以便安装在导管尖端上送至血管。支架的总厚度优选为100-1000微米,总长度为0.4-10cm。事实上,该类型可生物降解支架的一个重要的优点是,相对较长的支架、如长度超过3cm的支架,能容易地送入并放置在血管损伤部位。
关于用可生物降解聚合物(如聚-l-丙交酯)的编结丝形成可扩张球囊支架的方法已有报道(美国专利6,080,177)。也有一种形式的装置已被用于释放药物(美国5,733,327)。
一种优选的用于形成支架的聚合物材料是聚-l-或聚-dl-丙交酯(美国专利6,080,177)。如上所述,支架体和涂层可以是一体的,成为一个在整个支架中含有抗再狭窄化合物的可扩张丝支架。或者,可生物降解涂层可以被涂到预制的可生物降解体中,详见以下第二部分的描述。按后者,支架体可以由一种可生物降解聚合物如聚-l-丙交酯形成,涂层由第二种聚合物如聚-dl-丙交酯聚合物形成。涂层如果是被涂到预制支架上的,则涂层具有与以上描述基本相同的组成和厚度特征。
图4显示了一个刚描述的可生物降解支架中的细丝、例如螺旋丝带的横断面图,它具有分别形成的支架体和涂层。图中显示了一个内部的可生物降解的支架细丝36,在其所有侧面均涂有可生物降解的涂层38。一种示例性的涂层是由聚-dl-丙交酯形成的,含有20-40%重量的抗再狭窄药,如大环三烯免疫抑制化合物和60-80%重量的聚合物底材。在另一个实施方案中,涂层含45-75%重量的化合物和25-55%重量的聚合物基质。在以上两种实施方案中均可使用其它类的抗再狭窄化合物,如上面所述的那些。
可生物降解的支架有一个独特的优势,就是用一个装置治疗整个血管,它既可以和球囊成形术结合使用以便在有大的堵塞存在时预扩张血管,也可以作为预防性植入物放入将来可能发生堵塞的高风险患者体内。由于支架是可完全生物降解的,它不会像“全金属衣”、即一串含金属底材的药物洗脱支架那样影响患者以后在血管做非复杂手术的机会。
如以上所说,可以在涂层上掺入第二种活性剂,用于在植入后在希望的一定时间内从涂层中释放。或者,如果使用了第二种活性剂,若涂到支架体的涂层没有覆盖支架体的内表面,则可将第二种活性剂掺入到支架体细丝中。在以下第二部分叙述的关于金属丝支架体的涂层方法也适用于聚合物丝支架体。
第二部分:支架涂层方法
更详细地参考附图,图5A和5B是本发明的支架涂层工艺的示意图。在可相容的溶剂中溶解聚合物得到聚合物溶液40。将至少一种抗再狭窄化合物和,如果需要的话,第二种活性剂,以混悬液或溶液的形式用同种溶剂或不同的溶剂加入聚合物溶液中。将整个混合物置于加压储存器42中。储存器上连有一个液体加压泵44。
加压泵可以采用任何压力来源,只要能把混合溶剂以一个设计的速度推过溶液传输管46。正如精密给料系统领域所公知的,加压泵44由微型控制器(没图示)控制。例如:这样一个微型控制器可以含有4-轴自动给料装置(4-Axis Dispensing Robot,型号为I&J500-R和I&J750-R,可从FairLawn,NJ的I&J Fisnar公司获得,它可通过RS-232C交换界面由个人电脑控制;或精密给料系统如Automove A-400,其来自加拿大卡尔斯拜的Asymtek。一个用于控制RS232C界面的合适的软件程序可从包括Fluidmove系统,其也可由加拿大卡尔斯拜的Asymtek得到。
与储存器42相连的,例如与储存器的底部相连的是溶液导管48,它把溶剂混合物传输到支架的表面。可加压储存器42和导管48被装在一个可移动的支架上(没图示),它可使溶剂导管以微小的步长移动,例如每步0.2mm,或连续地沿支架的长轴方向移动(如图中箭头X1所示)。加压储存器42和导管46的可移动支架也能将导管的尖部(远端)沿Y1所示的方向以微小的步长移向或远离细丝的表面。
未涂层的支架被卡在转动的卡夹上,卡夹至少有一端与支架的内表面相接触。通过步进电机带动卡夹可以使支架以微小的角度沿轴向旋转,如每次0.5度,以使支架结构的最外表面可以被导管涂层,这是本领域公知的。如果需要,支架也可连续转动。精确定位低量液体传导装置的方法在X-Y-Z溶剂给料系统领域是公知的,可以用于本发明。
液体加压泵的活动、液体导管X1和Y1向定位以及支架R1向定位都是由数字控制器和计算机软件来控制,这样定量的溶液被精确地涂到支架表面所需要的地方,然后,溶剂可以被蒸发,支架表面剩下变硬的聚合物和活性剂涂层。溶剂混合物的粘度通常随溶剂的量变化,其范围2-2000厘泊,通常可能为300-700厘泊。或者,可将导管固定在固定的位置,支架除转动外还可沿其长轴方向移动完成涂层工艺。
X-Y-Z定位台和可移动的支架可以从I&J Fisnar采购。溶液导管尺寸最好是18-28计量规格的不锈钢注射管,连有可被锁定的连接器。这种导管可以从RI,East Providence的EFD公司得到。见EFD的特别用途的注射针选择指南。优选的注射针是再订购号从5118-1/4-B到5121-1/4-B的“无泊尔钝化不锈钢针,长度1/4”快速点对点注射充粒子或稠的材料”;再订购号为51150VAL-B的“椭圆的不锈钢针,在平带状沉积物上涂抹稠的浆料、密封剂和环氧物”;再订购号从5121-TLC-B到5125-TLC-B的“抗氰基丙烯酸酯凝结并为低粘度液体提供附加的沉积控制。压纹和衬聚四氟乙烯”。一种可任意使用的加压溶液储存器也可以从EFD得到,库存号1000Y5148到1000Y 5152 F。用于本发明的另一种针头是玻璃毛细管,内径约0.0005-0.002英寸,如约0.001英寸,在VWR目录中可以得到,目录号15401-560“微血球比溶剂管”,长度60mm,内径0.5-0.6mm。
在本生灯下,管子被进一步拉伸,得到用于精确涂层聚合物/药物/溶剂混合物的希望的尺寸。用于操作步进电机的可编程的微控制器和XYZ台可从Asymtek公司获得。本发明还包括使用一个以上的液体给料管共同形成涂层,或在同一涂层工艺中,使用一个以上的装配有不同注射针或含不同粘度的溶液或由多种溶液组成的不同的化学剂的可移动溶液储存器。卡夹和步进电机系统可以从NJ,Barrigton的Edmund Scientific购买。
如上所述,涂层通常被直接涂在支架的外支撑面,可能覆盖或不覆盖支架内表面的全部或一(或多)部分,覆盖的情况取决于如何控制以上所述的本发明的涂层系统,如图5A和5B所示。后图是用涂层材料52涂细丝50的顶部和侧面区域。或者,涂层或涂层混合物也可以直接涂到支架的内表面。一个细的导针可以穿过支架壁的一个或多个缺口处(即:窗户),从而使涂层混合物直接涂到支架内表面希望的位置。用此方法,就可以实现用含不同药物成分的不同涂层材料涂到细丝的内和外面。例如,细丝外表面涂层可含抗再狭窄化合物,细丝的内表面涂层可含有上面所提的第二活性剂之一,如抗血栓或抗凝血化合物。如果支架有足够大的直径,细的“L-型”导针能沿支架的长轴方向插入到支架的开放端以将支架的内表面涂层。
用于本发明的聚合物包括但并不仅限于:聚(d,l-乳酸)、聚(l-乳酸)、聚(d-乳酸)、乙烯乙烯醇共聚物(EVOH)、ε-己内酯、乙基乙烯基羟基化乙酸酯(EVA)、聚乙烯醇(PVA)、聚氧化乙烯(PEO)和其共聚物和混合物,被溶解于氯仿或丙酮或其他适用的溶剂中。所有这些聚合物都有用于系统循环的安全和低炎症史。
一种非聚合物涂层也可用于本发明,如通过离子连接涂到金属支架表面的依维莫司。
使用描述的涂层系统,会发现给支架表面涂层无论上、侧或里面都是可行的。通过仔细选择溶剂和聚合物的合适比率,可以调整溶液的粘度,从而使一些溶液可以沿着支柱的侧面向下移动,并在凝固前占据底部表面,见图5B。通过控制导管接近支架边缘的停留时间,聚合物被涂到支架边缘或底部的量就会被增减。在图3所示的实施方案中,首先将由纯聚合物和溶剂组成的底层34用本发明的涂层系统涂到支架表面24,然后将溶剂蒸发掉。然后涂上含生物活性剂的第二层聚合物涂层32。
如上所述,第二活性剂也可以被加入聚合物的混合物中。如:结晶形式的肝素可以被加入涂层中。将肝素结晶微粒化到粒度约为1-5微米,然后以悬浮液的形式加入聚合物溶液中。当按照本发明的工艺涂层时,肝素的适宜形式是那些在哺乳动物中显示生物活性的结晶态,包括肝素盐(即:肝素钠和低分子量肝素及其盐)。当药物释放型支架被放入血管壁时,如图8所示,靠近凝固的聚合物涂层表面的肝素晶体开始溶解,增加了聚合物的孔。当聚合物慢慢溶解,更多的肝素和生物活性剂以受控的方式被释放。
然而,参见图8,应注意到,并不总是需要在支架内表面涂层。例如,在支架内表面涂层增加了支架起皱的传导轮廓,使在小血管内的可操作性变小。并且,植入血管后内表面直接被通过支架的血流冲洗,导致支架内表面释放的药物流失在系统循环中。所以,在图3和图4所示的实施方案中,凝固的聚合物和活性剂大部分被涂在支架支撑的圆周的外面,其次是在侧面上。在一个优选的实施方案中,仅最小量的聚合物和活性剂被涂在支架的内表面。若需要,也可至少有一部分支架内表面不被涂层或裸露。
此外,图3和图4的涂层也可以有选择地涂到支架丝的表面。涂层的厚度应与用于组织中的生物活性涂层的体积相对应。限制一些范围的涂层是有利的,因为这些范围的涂层会导致放支架时的高损伤。
先在支架的表面均匀地涂上底层,以促进含生物活性剂涂层与支架的粘合,和/或帮助稳定在支架上的聚合物涂层。最初的涂层可以用本领域已知的任何方法涂层,或用本发明的精确给料系统涂层。使用不同的聚合物材料涂最初的涂层也在本发明内,如使用聚对亚苯基二甲基(聚(二氯-对-二甲苯)),或任何其他可以使金属底材和含生物活性剂的涂层能很好粘合的材料。聚对亚苯基二甲基(聚(二氯-对-二甲苯))可以采用等离子沉积或蒸气沉积技术,此技术是本领域公知的(见美国专利6,299,604)。在本发明的一个实施方案中,含肝素的不连续或连续的涂层涂在支架的内表面,而含本发明上述抗增殖药物的涂层涂在支架外表面。
当需要在金属支架底材上形成具有高的药物/聚合物底材比例,如药物含量占涂层重量40-80%的涂层时,最好在支架丝上涂一底层来稳定并牢固地将涂层粘在底材上。在沉积涂层材料前,底层可通过在一种合适的溶剂中溶胀来进一步处理,溶剂可以是例如丙酮、氯仿、二甲苯或它们的混合物。在实施例5中描述了该方法,用于制备具有高的依维莫司/聚-dl-丙交酯比例的支架。
其中,通过等离子沉积法在支架丝上形成聚对亚苯基二甲基底层,然后将该底层在二甲苯中溶胀,最后沉积涂层材料。该方法可用于生产在聚-dl-丙交酯聚合物底材中含50%药物或75%药物的涂层,涂层厚度仅为5-10微米。
如上所述,使用本发明的涂层系统生产完全可生物降解的支架也在本发明的范围内。先用顶部开放的“C-形”螺旋状槽以将要制造的支架形状制一个管状预制件,可以用给料系统向该槽内注入聚合物。预制件的外径是开放的,以便聚合物可被放入预制件中,通常用注射管的一个通道,若需要也可有多个;并同时建立支架均匀一致的边缘,因为聚合物会受预制件的限制。预制件可溶于一种溶剂中,但由此产生的可生物降解支架不溶于此溶剂。在注入聚合物并且聚合物溶液的溶剂已被蒸发后,可将装配组合放入可溶解预制件的溶液中,释放出完整的支架结构。用于制备预制件的有代表性的原料是蔗糖,它可以用标准的注塑技术制成希望的预制件形状。预制件的代表性溶剂是水。
第三部分、使用方法和性能特性
该部分描述了本发明的血管治疗方法和根据本发明所制的支架的性能特性。
A、方法
本发明的方法旨在减小有局部血管损伤或血管闭塞风险的患者再狭窄的危险和/或程度。典型的血管损伤是在血管造影术过程中打开部分闭塞的血管如冠状动脉或外周动脉时造成的。在血管造影术中,球囊导管被放于闭塞处,球囊远端充气和放气一或多次,迫使闭塞的血管打开。这种血管的扩张尤其涉及血管壁的表面创伤,可使其上的斑块移动,经常造成局部创伤,足以使血管随时间的过去而产生细胞增殖和再闭合反应。不奇怪,再狭窄的发生率和严重程度经常与血管造影术中所涉及的血管被牵拉的程度有关。特别是过度拉伸到35%或更高时,再狭窄的发生频率很高并且经常是很严重的,即血管闭塞。
在本发明的实践中,将支架以其收缩状态置于导管的远端,可以在导管腔内,或者以其收缩状态置于球囊的远端。然后将导管远端引导到损伤处或潜在闭合点并从导管上释放支架,例如,如果支架是自扩张型的,用拉发线释放支架到位点,或者,在球囊上通过球囊充气使支架扩张,直到支架与血管壁相接触,从而将支架植入血管壁组织。
图6显示了本发明的一个可完全生物降解的支架和将支架置入心血管系统的血管如冠状动脉内的导管。图中显示了部分放松状态的支架53,称作“药物螺旋支架”。该支架是自扩张的螺旋型支架,由聚乳酸形成并且含有一种或多种本发明的生物活性剂。
该螺旋支架用所述的预制件制成,预制件的最终扩张直径被设定为略大于用此螺旋支架治疗的血管内腔尺寸。除去预制件后,通过将药物螺旋支架的两端向反方向拧使其到较小半径,这样压缩其全长至一个可滑动鞘下,使螺旋的传输直径大约为最终扩张直径的1/3(在体温下)。药物螺旋支架的厚度足够小(约25-125微米),使其易于弯曲到更小的半径,形成与鞘的内径相当的压缩的螺旋。鞘被滑动地放在导管55上,该导管适于将压缩状态的支架导入目标血管。鞘54在其近端有一个把手56,通过它,血管成形术的操作者可以在导管尖端到达血管的适当位置时把鞘向后拉,从而完全释放药物螺旋。
导管55中央有一个直径约为0.014″的内腔,带有柔韧尖端58的导丝57可以在其内滑动。导管还有一个卢尔毂59,用于连接内腔到Y接头和止血阀,这是血管成形术领域公知的。有可滑动鞘的导管的外径范围在2-4F(法国尺寸);若治疗外周动脉会更大。
由于药物螺旋支架是可完全生物降解的,它不影响患者以后接受不复杂血管外科手术的机会,不像全金属衣那样。在某些神经和血管应用领域,裸金属螺旋支架放入血管中经常会产生血栓栓塞,甚至是完全闭塞,而令人惊奇的是,已经发现,已揭示结构中的生物相容性聚合物聚(dl-乳酸)(PDLA)及其混合物,可以提供合适的机械强度以支撑血管成形术后损伤的血管,并且不产生栓塞;因此是用于生产本发明药物螺旋支架的示例性材料。
支架一旦入位即开始释放活性化合物到血管内层的细胞中以抑制细胞增殖。图7A显示依维莫司从两个按照本发明制造的支架释放的动力学,每个支架有大约10微米厚的涂层(涂黑的正方形)。药物释放动力学是通过将支架浸入25%的乙醇溶液中得到的,该溶液可大大加快药物从支架涂层释放的速度。曲线图显示体内可预期的药物释放动力学,但经历的时间要长的多。
图7B显示从金属支架上的本发明涂层释放依维莫司的图形。上面的一组曲线显示直接涂到金属表面的涂层的药物释放。下面一组曲线(显示缓慢释放)是通过在金属支架表面先涂一层聚对亚苯基二甲基底层或初级涂层,然后再涂本发明的涂层系统所获得的。可以看出,涂有底层使涂层与支架表面的机械粘附增加,使可生物降解涂层的分解减慢,药物释放也减慢。当需要强粘附的支架涂层以经得住药物洗脱支架在导管和/或血管内弯曲操作时反复的磨损时;和/或需要支架置入后在置入部位药物释放的速度减慢以延长对动脉粥样硬化过程的治疗时,这样的结构是有用的。
图8显示一个横截面图,图中可以看到已植入一个支架62的血管区域60,所述支架的涂层丝例如丝64带有涂层66。该图显示抗再狭窄化合物从每个丝区域释放到周围的血管壁区域。经过一段时间,形成的血管壁的平滑肌细胞开始在支架内或穿过支架网或螺旋空隙生长,最后形成吞没支架双面的连续的内细胞层。如果支架植入是成功的,以后在支架位置的血管的闭塞程度将小于50%,即在血管内保持血流通道的横截面直径至少是植入时已扩张支架直径的50%。
在如Schwartz等人所述的猪再狭窄动物模型(“球囊血管成形术后再狭窄--一个猪冠状动脉的实用的增殖模型”,Circulation 82:(6)2190-2200,1990年12月)中进行的试验证实了本发明的支架限制再狭窄程度的能力,以及该支架优于现有的和经过测试的支架的优越性,尤其对严重的血管损伤的病例,即血管的拉伸大于35%的病例。研究在实施例4中进行了总结。
简言之,研究比较了几种支架在植入28天后再狭窄的程度,支架包括:裸金属支架、聚合物涂层支架、包含高或低浓度的雷帕霉素和依维莫司的聚合物涂层支架。
实施例4的表1显示雷帕霉素(Rapa-高或Rapa-低)和依维莫司(C-高或C-低)支架大大减少了再狭窄的水平,高剂量依维莫司支架的再狭窄最小。在低损伤动物研究中获得了同样的结果(表2)。
图9A-9C是植入裸金属S-支架(从加洲Bewport Beach的BiosensoresInternational Inc获得)后28天新生内膜的支架横断面图例。图10A-10C是聚合物涂层(无药)S-支架的新内膜形成的例子。图11A-11C和图12A-12C是依维莫司/聚合物涂层支架的新内膜形成。总的来说,依维莫司涂层支架所治疗的血管愈合良好,内皮层建立良好,28天血管完全愈合并达到血管稳态。图13是一个放大91倍的血管横断面,显示支架植入后28天血管腔内愈合和建立的内皮层。
照片显示,在28天消除再狭窄的最佳结合是C-高或C-U高(见实施例4),它们在18.7mm长的支架上分别含325mg和275mg依维莫司。对远系繁殖的幼猪随访28天的数据预测,与目前市场上的裸金属支架(S-支架)相比,再狭窄率减少50%。数据也显示,在同样的支架/聚合物传输平台上,依维莫司优于或至少相当于180mg雷帕霉素。形态度量分析(实施例4)支持这些结果。
图15显示了在动物实验中,血管被球囊过度拉伸(通过球囊/对动脉比率,即(B/A比率)来测量)和血管损伤的关系。该数据显示了用过度扩张的血管成形术球囊造成高度控制的血管损伤是在猪模型中造成可预测和已知的血管损伤的合理的精确方法。
图14显示选择涂到S-支架上的聚合物中的药物剂量的“最佳拟合”线性回归曲线,损伤度与随访时狭窄面积相关。“狭窄面积”是一个由形态度量分析确定的新内膜形成的精确指标。从图上可看出,在测试的样品组中仅高含量的依维莫司涂层支架相对损伤度增加显示负性斜率。此分析提示C-高涂层可能能够在损伤的冠状动脉中控制再狭窄,这实际上与损伤度无关。其它涂层配方均不能显示这一独特特性。
从前述中可以看到,本发明能满足多种目的,并有多种特性。
一方面,发明提供了含高药物/聚合物比率(例如,40-80%重量的药物)的可生物降解的支架涂层。这一特性使从低轮廓的支架可以在较长的时间内连续释放抗再狭窄化合物。同时,聚合物分解的成分例如在生物腐蚀过程中释放的乳酸酯和乳酸的总量相对较少,从而使可能的副反应例如由支架涂层的生物腐蚀引起的刺激减到最小。
另一方面,本发明提供了一种治疗或抑制再狭窄的改良的方法。该方法涉及大环三烯免疫抑制化合物在支架聚合物涂层中的新组合,该方法提供了至少与现有技术中最好的支架相同的抗再狭窄效果,另外还增加了优于现有技术的优点,即该方法的功效似乎与损伤的程度无关,并且该方法可以提供支架血管更大程度的内皮化。
最后,本发明提供了可完全生物降解的支架,该支架具有刚提到的优点,并且比金属支架在设计上更有灵活性,尤其是在支架总长度和已治疗血管的将来手术可能性方面。
以下实施例举例说明了本发明的支架制造和使用的各方面。但本发明不仅限于这些范围。
                        实施例1
                 依维莫司及其衍生物的制备
步骤A、2-(叔丁基二甲基硅烷基)氧基乙醇(TBS乙二醇)的合成
将154ml无水THF和1.88g NaH在氮气氛下在带有冷凝器的500ml圆底烧瓶中搅拌。向烧瓶中加入4.4ml无水乙二醇,搅拌45分钟后生成大量沉淀物。向烧瓶中加入11.8g叔丁基二甲基氯硅烷并继续剧烈搅拌45分钟。将形成的混合物倒入950ml乙醚中。用420ml盐水洗乙醚,溶液用硫酸钠干燥。将产物通过真空蒸发乙醚进行浓缩,然后通过快速色谱法用27×5.75cm充硅胶柱进行纯化,用己烷/Et2O(75∶25 v/v)溶剂系统洗脱。将产品在0℃保存。
步骤B、2-(叔丁基二甲基硅烷基)氧基乙醇三氟甲磺酸酯(TBS乙二醇Trif)的合成
氮气氛及剧烈搅拌下,将4.22g TBS乙二醇和5.2g 2,6-二甲基吡啶在装有冷凝器的100ml双颈烧瓶中混合。在35-45分钟内缓慢加入10.74g三氟甲磺酸酐,生成黄棕色溶液。然后加入1ml盐水结束反应,溶液用100ml盐水洗5次,最终pH值为6-7。将溶液用硫酸钠干燥,在真空中蒸发二氯甲烷进行浓缩。将产物通过快速色谱法用24×3cm充硅胶柱进行纯化,用己烷/Et2O(85∶15 v/v)溶剂系统洗脱,然后在0℃下保存。
步骤C、40-O-[2-(叔丁基二甲基硅烷基)氧基]乙基-雷帕霉素(TBS Rap)的合成
在50ml烧瓶中,将400mg雷帕霉素、10ml甲苯和1.9ml 2,6-二甲基吡啶混合并在55-57℃下搅拌。在另一个3ml的隔膜小瓶中加入1ml甲苯,再加入940μl 2,6-二甲基吡啶,接着加入2.47g的TBS乙二醇Trif。把小瓶内的混合物加到50ml的烧瓶中,反应在搅拌下进行1.5小时。向反应烧瓶中再加入480μL 2,6-二甲基吡啶和另加的1.236g TBS乙二醇Trif,继续搅拌反应1小时。最后再加入480μL 2,6-二甲基吡啶和1.236g TBS乙二醇Trif到混合物中,将混合物再搅拌1-1.5小时。将生成的棕色溶液用真空多孔玻璃过滤器过滤。用甲苯洗涤结晶状的沉淀物直到所有颜色被去掉。然后用60ml饱和NaHCO3溶液洗涤滤液2次,然后再用盐水洗。溶液用硫酸钠干燥,真空浓缩。用少量己烷/EtOAc(40∶60 v/v)溶剂溶解产物,用33×2cm快速硅胶色谱柱纯化,用同样的溶剂洗脱。真空除去溶剂,将产物在5℃下存放。
步骤D、40-O-(2-羟基)乙基-雷帕霉素(依维莫司)的合成工艺
向耐热玻璃碟(150×75mm)中加满冰并放置在搅拌盘上。加入少量水。先在一个小的玻璃瓶中用8ml甲醇溶解60-65mg的TBS-雷帕霉素。向小瓶中加入0.8ml 1N的HCl,将溶液搅拌45分钟,然后加3ml饱和NaHCO3水溶液进行中和。向溶液中加入5ml盐水,然后加入20ml EtOAc,产生两相的混合物。混合两相,再用分液漏斗排掉水层。剩下的溶液用盐水洗直到最终pH为6-7,然后用硫酸钠干燥。用多孔玻璃过滤器除去硫酸钠,然后真空蒸除溶剂。将得到的浓缩物溶于EtOAc/甲醇(97∶3)中,然后用23×2cm快速硅胶色谱柱纯化,用同样的溶剂洗脱。真空除去溶剂,将产物在5℃下存放。
                        实施例2
    制备在聚-d,l-丙交酯涂层中含依维莫司的支架
在室温下将100mg的聚-d,l-丙交酯溶于2ml丙酮。将5mg依维莫司放在小瓶中,加入400μL丙交酯溶液。用微处理器控制的注射泵精确给料10μL含药物的丙交酯溶液到支架支柱的顶面。溶剂蒸发后在支架上产生均匀的含药物的单一聚合物层。
以同样的方法将15μL溶液涂到支架支柱的顶面和侧面,产生涂在支架支柱顶部和侧面的单层涂层。
                        实施例3
在体外从在聚-d,l-丙交酯涂层中含依维莫司的支架上释放药物
将涂层支架放入2ml pH 7.4的含25%ETOH的磷酸盐缓冲液中,用0.05%(w/v)叠氮化钠防腐并将温度维持在37℃,构建体外药物释放。定时抽出全部缓冲液进行取样以进行药物测量,同时放入同体积的新的缓冲液(无限沉淀)。图7图示了从2个用此方法涂单一聚合物涂层的相似支架的药物释放情况。
                        实施例4
                    动物植入实验
A、猪的安全性和剂量研究的QCA结果
基本原理:
正如所知,药物洗脱支架治疗最具挑战性的病症是严重损伤的血管,因为已知血管损伤程度的增加直接导致再狭窄(新内膜形成)程度的增加。实验是在猪身上进行的,药物涂层支架植入的靶血管用血管成形术球囊严重损伤(血管过度拉伸损伤平均约36%)。这引起血管内膜层和中间层的严重撕裂和拉伸,导致植入支架28后的血管充溢再狭窄。用这种方法,可以在同一金属支架/聚合物平台上评估各种不同剂量的药物以及药物与聚合物的不同重量比率在支架植入28天后对减少再狭窄的相对有效性。
缩写
“裸支架”指18.7mm裸金属波纹环支架(即,目前市场上由BiosensorsIntl.Inc制造的“S-支架”);
“C-高”指18.7mm的支架,在PDLA(聚-dl-乳酸)聚合物涂层中含有325mg的依维莫司。
“C-低”指18.7mm的支架,在PDLA聚合物涂层中含有180mg依维莫司。
“雷帕霉素-高”指18.7mm的支架,在PDLA聚合物涂层中含有325mg雷帕霉素。
“雷帕霉素-低”指18.7mm的支架,在PDLA聚合物涂层中含有180mg雷帕霉素。
“C-U高”指18.7mm的支架,在极薄的PDLA聚合物涂层中含有275mg依维莫司(药物与聚合物的重量比是37%)。
“C-U低”指18.7mm的支架,在极薄的PDLA聚合物涂层中含有180mg依维莫司或等同物(药物与聚合物的重量比是37%)。
“聚合物支架”指仅有PDLA聚合物涂层的18.7mm的S-支架。
“B/A”:最终扩张的球囊与动脉血管的比率,表示血管被过度拉伸的程度。
“平均内腔损失(MLL)”:植入时测量支架内腔3次,3次数据的平均值减去随访造影时3次测量的平均值的差,反映了支架内新内膜的形成量。
方法
将由波状环的金属线网支架(即S-支架)和聚合物涂层组成的药物洗脱支架植入到远系繁殖的幼猪(也可植入犹卡塔小猪持续超过28天),涂层使用不同剂量的依维莫司或雷帕霉素。在植入时,用QCA(定量冠脉造影)测定植入支架前后的血管直径。在28天或在下表规定的更长时间,在安乐死之前对动物在支架区再做造影。
动物按许可的方案安乐死后,取出动物的心脏,用甲醛溶液加压注入冠状动脉。含支架的冠状动脉部分从心脏的表面被切除随后被固定在丙烯酸塑料板上,用钻石锯切割出横断面。含有血管最近端、中间、最远端的各50微米厚的丙烯酸材料切片经光学磨光后安装在显微镜的滑片上。
用一个带有数码像机的显微镜摄出安装在滑片上的血管横断面的高分辨率图象。图象按以下程序做组织形态分析。
使用计算机图象处理系统Image Pro Plus 4.0通过基于PC系统的A.G.Heinze显微镜进行组织形态的分析。
1、平均横截面面积和内腔厚度(由内膜/新内膜-内腔边划定的面积);新内膜(在内腔和内弹性薄层即IEL间的面积,当IEL消失,则为内腔和残留的中间膜或外弹性薄层EEL间的面积);中间(IEL和EEL间的面积);血管尺寸(由EEL圈定的面积,但不包括外膜面积);外膜面积(在周边外膜组织,脂肪组织和心肌以及EEL之间的面积)。
2、损伤度。为量化血管损伤的程度,使用以不同血管壁结构撕裂的长度和量为基础的评分。损伤度被计算如下:
0=完整的IEL;
1=IEL被轻度撕裂,暴露了表中层(较小损伤);
2=IEL被中度撕裂,暴露了更深的中层(中度切开);
3-EEL被撕裂,暴露了外层。mm2
下表是QCA分析的结果(测量由于再狭窄产生的平均内腔损失)。下表“新内膜面积”列中的数据显示了随访时从猪取下的血管和支架的形态学分析结果
表1  “高损伤”实验的结果
 装置说明 (B/A)比(平均) 随访时间 平均内腔损失(mm) 新内膜面积(mm2) 支架号
 裸金属支架 1.33  28  1.69  5.89 31,39,40,45,47,50
 聚合物涂层支架 1.36  28  2.10  5.82 32,41,43,48,51,60
 R-高 1.39  28  1.07  3.75 42,44,49,65,69,73
 R-低 1.42  28  0.99  2.80 52,56,61,64,68,72
 C-高 1.37  28  0.84  3.54 54,55,59,63
 C-低 1.36  28  1.54  3.41 53,57,58,62,66,70,74
 C-U高 1.36  28  0.85  2.97 67,75,92,103
B、低损伤研究:
为进一步确定在轻度损伤的血管中依维莫司的最佳剂量,尤其是对简单的冠状动脉疾病和单一的未处理过病变的患者,植入依维莫司药物洗脱支架造成中度到低度的过度拉伸损伤(约15%)。用农场猪进行30天的实验,用成年尤卡塔小猪进行植入3个月的安全性研究。血管造影结果如下:
               表2“低损伤”实验的QCA结果
装置说明 (B/A)比 植入后的天数 平均内腔损失(mm) 新内膜面积(mm2)     支架号
 裸金属支架 1.14  28  0.95  2.89 20,22,26,29
 裸金属支架 1.13  90 76,80,84,87,91
 C-U高 1.15  28  0.60  2.14 94,96,98,102
 C-U低 1.09  28  0.49  2.26 93,95,97,100,101
 C-U高 1.15  90 77,81,85,86,90
以上数据预示,依维莫司的C-U低或C-U高剂量可在低至中度损伤的血管中降低新内膜形成45-48%。
C、形态测量分析
用计算机测量每个支架内总的截面面积和在支架内形成的新组织(新内膜)的截面面积,计算出狭窄面积百分比。每种药物和聚合物配方的平均血管损伤度、新内膜面积和狭窄面积百分比(每一支架测量三张片子,取平均值),显示在下表中。
                    表3“高损伤”实验结果
  装置说明 损伤度 随访时间 新内膜面积(mm2) 狭窄面积(%)     支架号
 裸金属支架 1.9  28  5.89  0.72 31,39,40,45,47,50
 聚合物涂层支架 2.11  28  5.82  0.70 32,41,43,48,51,60
 R-高 2.10  28  3.75  0.55 42,44,49,65,69,73
 R-低 1.90  28  2.80  0.43 52,56,61,64,68,72
 C-高 1.89  28  3.54  0.38 54,55,59,63
 C-低 2.1  28  3.41  0.53 53,57,58,62,66,70,74
 C-U高 2.13  28  2.97  0.45 67,75,92,103
形态测量分析是在猪冠状动脉模型中测量支架内再狭窄的高度精确的方法。在高损伤的模型中,C-高配方在高度损伤实验28天时产生最低量的新内膜形成;而C-U高组有最高的损伤程度,但仍能维持低百分比的狭窄面积-0.45。因此,此数据独立的证实了QCA分析的发现,支持人体实验优选的配方应是C-U高。
D、组织学分析
将C-U高和雷帕霉素-低的幻灯片呈给一个有经验的心脏病理学家,对血管横切面新愈合的血管内腔的炎症、纤维素蛋白、内皮化情况进行审视。未发现由雷帕霉素和依维莫司洗脱支架引起的组织学变化有不同。总的来说,28天时血管已形成完好的内皮层恢复其平衡,达到完全愈合。图13是一个放大91倍的血管横断面例子,显示支架植入28天后血管内腔的愈合及内皮层的建立。
E、与已发表结果的比较
Carter等人已发表了使用Palmaz Schatz金属支架的雷帕霉素涂层支架在猪身上实验的结果。下表是已发表的Carter的结果和Biosensors实验结果的比较:
                        表-4
  装置说明 血管过度拉伸(%) 平均后期损失(mm) 标准偏差(mm) 新内膜截面面积(mm2)
S-支架裸金属对照 33.5%±9.2%   1.80     ±0.5  7.6
S-支架仅涂聚合物 34.9%±4.8%   2.02     ±0.8  8.5
S-支架聚合物/雷帕霉素(325mg) 32.9%±10.1%   0.66     ±0.2  3.27(对照的-57%)
S-支架聚合物/依维莫司(325mg) 36.8%±8.5%   0.74     ±0.3  3.61(对照的-50%)
PS支架BARE*对照 10-20%   1.19     ---  4.5
PS支架仅涂聚合物 10-20%   1.38     ---  5.0
PS雷帕霉素洗脱支架*166mg 10-20%   0.70     ---  2.9(对照的-33.5%)
PS雷帕霉素洗脱支架*166mg(缓释) 10-20%   0.67     ---  2.8(对照的-37.7%)
PS雷帕霉素洗脱支架*450mg 10-20%   0.75     ---  3.1(对照的-31.1%)
                    实施例5
            高药物含量支架的制备
先用等离子沉积工艺在市售的14.6mm长的金属波状环支架(Biosensors Intl的S-支架,波状环设计)上涂上约2微米厚的聚对亚苯基二甲基“C”底层。然后将涂有聚对亚苯基二甲基的支架放在二甲苯中在环境温度下过夜。通过将100mg的聚乳酸(PDLA)溶解在2ml丙酮中制备含有50μg/μL PDLA的聚-d,l-乳酸储备液。
为了制备药物与聚合物的比率为50%的涂层支架,将5mg依维莫司溶于100μL PDLA储备液。另加20μL丙酮以促进溶液的分散。从二甲苯中取出支架,小心地把溶剂蘸干。在每个支架的外表面给料总共5.1μL涂层溶液。将支架在室温下干燥并置于干燥器中干燥过夜。由此使每个支架在212μg PDLA中含有212μg依维莫司。
为了制备药物与聚合物的比率为75%的涂层支架,将5mg依维莫司与33.3μL PDLA储备液混合。另加33.3μL丙酮使混合物溶解。按照以上描述从二甲苯中取出支架并蘸干。在每个支架的外表面给料总共2.8μL涂层溶液。将支架在室温下干燥并置于干燥器中干燥过夜。由此使每个支架在70μg PDLA中含有212μg依维莫司。
成品支架的依维莫司/PDLA涂层厚度为约5微米,或呈现浅乳白色外观,该涂层在顶面和侧面平滑分布并且与金属支柱表面牢固连接。

Claims (13)

1、一个用于放置在血管损伤部位以抑制该部位的再狭窄的血管内支架,其包含:
由一个或多个细丝形成的支架体;
涂在一个或多个细丝上的药物释放涂层,该涂层由(i)20-60%重量比的聚合物底材和(ii)40-80%重量比的抗再狭窄化合物组成;和
在支架体细丝和所述涂层之间的聚合物底层,
所述支架可以从收缩状态扩张,在收缩状态下,可以将支架通过导管传送到血管损伤部位,在扩张状态时,支架涂层与血管的损伤部位相接触,
所述涂层可有效地释放一定量的化合物以抑制损伤部位的再狭窄。
2、权利要求1所述的支架,其中的支架体是金属细丝结构,底层由聚对亚苯基二甲基聚合物形成并且厚度为1-5微米,涂层为可生物降解的聚合物并且厚度为3-30微米。
3、权利要求1所述的支架,其中的支架体是金属细丝结构,药物释放涂层由选自聚甲基丙烯酸甲酯、乙烯乙烯醇共聚物和聚-dl-丙交酯的聚合物形成。
4、权利要求1所述的支架,其中所述支架体是由聚-l-或聚-dl-乳酸聚合物形成的,药物释放涂层是由聚-dl-丙交酯形成的。
5、权利要求1至4任意一项所述的支架,其中所述的抗再狭窄化合物是大环三烯化合物。
6、权利要求5所述的支架,其中所述的化合物具有如下结构
其中,(i)当R’是H时,R是H或CH2-X-OH,并且X是直链或支链的含1-7个碳原子的烷基,或者(ii)R’和R中至少有一个为以下形式:
其中m是1-3的整数,R1和R2分别是氢或具有1-3个碳原子的烷基,或者R1和R2与它们所连接的氮原子一起形成具有4个碳原子的饱和杂环。
7、权利要求6所述的支架,其中R’是H,R是CH2-X-OH,X是-CH2
8、权利要求5所述的支架,其中所述的化合物具有如下结构:
其中R是CH2-X-OH,X是含有1-7个碳原子的直链烷基。
9、权利要求6-8任意一项所述的支架,其中所述化合物在涂层中的含量为50%-75%重量。
10、用于抑制血管损伤部位再狭窄的权利要求1-9中任意一项所述的支架。
11、权利要求10所述的支架,其用于治疗在血管造影术中由于血管直径被过度拉伸至少30%而产生的血管损伤。
12、一个用于放置在血管损伤部位以抑制该部位的再狭窄的血管内支架,其包含:
由一个或多个细丝形成的支架体;
涂在一个或多个细丝上的药物释放涂层,该涂层由聚合物底材和抗再狭窄化合物组成,所述抗再狭窄化合物具有如下结构:
其中R是CH2-X-OH,X是含有1-7个碳原子的直链或支链烷基;和
在支架体细丝和所述涂层之间的聚合物底层,
所述支架可以从收缩状态扩张,在收缩状态下,可以将支架通过导管传送到血管损伤部位,在扩张状态时,支架涂层与血管的损伤部位相接触,
所述涂层可有效地释放一定量的化合物以抑制损伤部位的再狭窄。
13、权利要求12所述的支架,其中X是CH2
CN038093111A 2002-04-24 2003-04-24 药物释放型血管内支架 Expired - Lifetime CN1649551B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/133,814 US6939376B2 (en) 2001-11-05 2002-04-24 Drug-delivery endovascular stent and method for treating restenosis
US10/133,814 2002-04-24
PCT/US2003/012750 WO2003090818A2 (en) 2002-04-24 2003-04-24 Drug-delivery endovascular stent and method for treating restenosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010102003218A Division CN101862233B (zh) 2002-04-24 2003-04-24 药物释放型血管内支架和治疗再狭窄的方法

Publications (2)

Publication Number Publication Date
CN1649551A true CN1649551A (zh) 2005-08-03
CN1649551B CN1649551B (zh) 2010-08-11

Family

ID=29268785

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010102003218A Expired - Lifetime CN101862233B (zh) 2002-04-24 2003-04-24 药物释放型血管内支架和治疗再狭窄的方法
CN038093111A Expired - Lifetime CN1649551B (zh) 2002-04-24 2003-04-24 药物释放型血管内支架
CNA03809309XA Pending CN1735402A (zh) 2002-04-24 2003-04-24 含大环三烯化合物的聚合物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010102003218A Expired - Lifetime CN101862233B (zh) 2002-04-24 2003-04-24 药物释放型血管内支架和治疗再狭窄的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA03809309XA Pending CN1735402A (zh) 2002-04-24 2003-04-24 含大环三烯化合物的聚合物组合物

Country Status (10)

Country Link
US (6) US6939376B2 (zh)
EP (6) EP2417943B1 (zh)
JP (6) JP2005523119A (zh)
CN (3) CN101862233B (zh)
AT (1) ATE451075T1 (zh)
AU (3) AU2003231757B2 (zh)
DE (1) DE60330455D1 (zh)
ES (4) ES2514391T3 (zh)
HK (3) HK1177882A1 (zh)
WO (2) WO2003090684A2 (zh)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101264351B (zh) * 2008-04-07 2011-08-24 易生科技(北京)有限公司 复合涂层心血管药物洗脱支架及其制备方法
CN102481195A (zh) * 2009-04-01 2012-05-30 米歇尔技术公司 涂覆支架
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN104203959A (zh) * 2012-06-08 2014-12-10 百多力股份公司 雷帕霉素40-o-环状烃酯、组合物和方法
CN104592254A (zh) * 2015-02-08 2015-05-06 福建省微生物研究所 依维莫司的合成方法
CN105566348A (zh) * 2015-12-31 2016-05-11 哈药集团技术中心 一种依维莫司的制备方法
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
CN108720971A (zh) * 2018-01-28 2018-11-02 杭州市第人民医院 一种可控抗菌气管支架
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device

Families Citing this family (341)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7419678B2 (en) * 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US7175658B1 (en) * 2000-07-20 2007-02-13 Multi-Gene Vascular Systems Ltd. Artificial vascular grafts, their construction and use
DE60112318D1 (de) 2000-10-16 2005-09-01 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
EP1258230A3 (en) 2001-03-29 2003-12-10 CardioSafe Ltd Balloon catheter device
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8080048B2 (en) * 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US20030135266A1 (en) * 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7270668B2 (en) * 2001-12-03 2007-09-18 Xtent, Inc. Apparatus and methods for delivering coiled prostheses
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US7182779B2 (en) 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7309350B2 (en) 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7147656B2 (en) 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US20040186551A1 (en) 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US7351255B2 (en) * 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6645547B1 (en) * 2002-05-02 2003-11-11 Labcoat Ltd. Stent coating device
US7270675B2 (en) * 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
WO2004002367A1 (fr) * 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Stent eluant des medicaments
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
US7149587B2 (en) 2002-09-26 2006-12-12 Pacesetter, Inc. Cardiovascular anchoring device and method of deploying same
US8303511B2 (en) * 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
US6971813B2 (en) * 2002-09-27 2005-12-06 Labcoat, Ltd. Contact coating of prostheses
AU2003301246A1 (en) * 2002-10-15 2004-05-04 Norbert Thompson Parylene-coated silicone t-tubes and method of use thereof
US20040143321A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US20060121080A1 (en) 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
US20050070989A1 (en) * 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
JP2006514848A (ja) * 2002-11-13 2006-05-18 セタゴン インコーポレーティッド 多孔質層を有する医療装置およびその作製方法
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060002968A1 (en) * 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8715771B2 (en) * 2003-02-26 2014-05-06 Abbott Cardiovascular Systems Inc. Coated stent and method of making the same
US20090093875A1 (en) 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
WO2004082525A2 (en) 2003-03-14 2004-09-30 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
ATE526038T1 (de) 2003-03-28 2011-10-15 Innovational Holdings Llc Implantierbares medizinprodukt mit kontinuierlichem mittel-konzentrationsgefälle
US7241308B2 (en) 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US7229979B2 (en) * 2003-06-23 2007-06-12 Immune Modulation, Inc. Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US6840569B1 (en) * 2003-07-22 2005-01-11 Arthur Donald Leigh Caravan
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
US20050049693A1 (en) * 2003-08-25 2005-03-03 Medtronic Vascular Inc. Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease
US20050048194A1 (en) * 2003-09-02 2005-03-03 Labcoat Ltd. Prosthesis coating decision support system
US20050058768A1 (en) * 2003-09-16 2005-03-17 Eyal Teichman Method for coating prosthetic stents
JP2007508121A (ja) * 2003-10-14 2007-04-05 キューブ メディカル エーエス 血管形成術用バルーン
US20050080475A1 (en) * 2003-10-14 2005-04-14 Xtent, Inc. A Delaware Corporation Stent delivery devices and methods
US7553324B2 (en) * 2003-10-14 2009-06-30 Xtent, Inc. Fixed stent delivery devices and methods
US7192440B2 (en) * 2003-10-15 2007-03-20 Xtent, Inc. Implantable stent delivery devices and methods
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US7403966B2 (en) * 2003-12-08 2008-07-22 Freescale Semiconductor, Inc. Hardware for performing an arithmetic function
US7326236B2 (en) 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
US20070156225A1 (en) * 2003-12-23 2007-07-05 Xtent, Inc. Automated control mechanisms and methods for custom length stent apparatus
EP1699527A1 (en) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
DE102004029611A1 (de) * 2004-02-06 2005-08-25 Restate Patent Ag Implantat zur Freisetzung eines Wirkstoffs in ein von einem Körpermedium durchströmtes Gefäß
ES2632124T3 (es) * 2004-02-28 2017-09-11 Hemoteq Ag Revestimiento biocompatible, método y utilización de superficies médicas
ES2315745T3 (es) * 2004-03-01 2009-04-01 Terumo Kabushiki Kaisha Procedimiento para la fabricacion de derivados o-alquilados de rapamicina.
US7695731B2 (en) * 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050228477A1 (en) * 2004-04-09 2005-10-13 Xtent, Inc. Topographic coatings and coating methods for medical devices
US8353896B2 (en) 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US8512219B2 (en) 2004-04-19 2013-08-20 The Invention Science Fund I, Llc Bioelectromagnetic interface system
US8092549B2 (en) 2004-09-24 2012-01-10 The Invention Science Fund I, Llc Ciliated stent-like-system
US8337482B2 (en) 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US7850676B2 (en) 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US7998060B2 (en) 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling delivery device
US8361013B2 (en) 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
US7857767B2 (en) 2004-04-19 2010-12-28 Invention Science Fund I, Llc Lumen-traveling device
US8024036B2 (en) 2007-03-19 2011-09-20 The Invention Science Fund I, Llc Lumen-traveling biological interface device and method of use
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
WO2005110435A1 (en) * 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US20050255230A1 (en) * 2004-05-17 2005-11-17 Clerc Claude O Method of manufacturing a covered stent
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US20050288766A1 (en) * 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060029720A1 (en) * 2004-08-03 2006-02-09 Anastasia Panos Methods and apparatus for injection coating a medical device
US8980300B2 (en) 2004-08-05 2015-03-17 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060069424A1 (en) * 2004-09-27 2006-03-30 Xtent, Inc. Self-constrained segmented stents and methods for their deployment
US20060085065A1 (en) * 2004-10-15 2006-04-20 Krause Arthur A Stent with auxiliary treatment structure
US8388677B2 (en) 2004-10-29 2013-03-05 Boston Scientific Scimed, Inc. Anti-thrombogenic and anti-restenotic vascular medical devices
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7481835B1 (en) * 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US20060127443A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US8057543B2 (en) * 2005-01-28 2011-11-15 Greatbatch Ltd. Stent coating for eluting medication
US7749553B2 (en) * 2005-01-31 2010-07-06 Boston Scientific Scimed, Inc. Method and system for coating a medical device using optical drop volume verification
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US9381279B2 (en) 2005-03-24 2016-07-05 Abbott Cardiovascular Systems Inc. Implantable devices formed on non-fouling methacrylate or acrylate polymers
US7700659B2 (en) * 2005-03-24 2010-04-20 Advanced Cardiovascular Systems, Inc. Implantable devices formed of non-fouling methacrylate or acrylate polymers
CA2603332C (en) * 2005-03-31 2013-09-10 Conor Medsystems, Inc. System and method for loading a beneficial agent into a medical device
RU2007140909A (ru) 2005-04-04 2009-05-20 Синексус, Инк. (Us) Устройство и способы лечения заболеваний околоносовых пазух
US7402168B2 (en) * 2005-04-11 2008-07-22 Xtent, Inc. Custom-length stent delivery system with independently operable expansion elements
US8778375B2 (en) * 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
US8043323B2 (en) 2006-10-18 2011-10-25 Inspiremd Ltd. In vivo filter assembly
US8961586B2 (en) 2005-05-24 2015-02-24 Inspiremd Ltd. Bifurcated stent assemblies
US10070977B2 (en) 2005-05-24 2018-09-11 Inspire M.D. Ltd Stent apparatuses for treatment via body lumens and methods of use
US20060282149A1 (en) * 2005-06-08 2006-12-14 Xtent, Inc., A Delaware Corporation Apparatus and methods for deployment of multiple custom-length prostheses (II)
AU2011256902B2 (en) * 2005-07-15 2015-03-12 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20070020312A1 (en) * 2005-07-20 2007-01-25 Desnoyer Jessica R Method of fabricating a bioactive agent-releasing implantable medical device
WO2007040485A1 (en) * 2005-09-22 2007-04-12 Novovascular, Inc. Stent covered by a layer having a layer opening
US20070104753A1 (en) * 2005-11-04 2007-05-10 Aiden Flanagan Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
CN101336315B (zh) * 2005-12-07 2012-12-19 特拉维夫大学拉莫特有限公司 药物递送复合结构
US20070142903A1 (en) * 2005-12-15 2007-06-21 Dave Vipul B Laser cut intraluminal medical devices
US7842312B2 (en) * 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
WO2007081530A2 (en) * 2006-01-03 2007-07-19 Med Institute, Inc. Endoluminal medical device for local delivery of cathepsin inhibitors
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
US20070179587A1 (en) * 2006-01-30 2007-08-02 Xtent, Inc. Apparatus and methods for deployment of custom-length prostheses
EP1984040A1 (en) 2006-01-31 2008-10-29 Multi Gene Vascular Systems, Inc. Drug-eluting intravascular prostheses and methods of use
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
CA2646885A1 (en) 2006-03-20 2007-09-27 Xtent, Inc. Apparatus and methods for deployment of linked prosthetic segments
KR101520408B1 (ko) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
JP5102200B2 (ja) * 2006-03-30 2012-12-19 テルモ株式会社 生体内留置物
JPWO2007116646A1 (ja) * 2006-04-04 2009-08-20 テルモ株式会社 生体内留置物
US9198563B2 (en) 2006-04-12 2015-12-01 The Invention Science Fund I, Llc Temporal control of a lumen traveling device in a body tube tree
US20080058785A1 (en) 2006-04-12 2008-03-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Autofluorescent imaging and target ablation
US7879086B2 (en) * 2006-04-20 2011-02-01 Boston Scientific Scimed, Inc. Medical device having a coating comprising an adhesion promoter
US20070254003A1 (en) * 2006-05-01 2007-11-01 Pu Zhou Non-sticky coatings with therapeutic agents for medical devices
US20070276486A1 (en) * 2006-05-25 2007-11-29 E. Benson Hood Laboratories Coated tracheostomy tube and stoma stent or cannula
US20080097620A1 (en) * 2006-05-26 2008-04-24 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US9561351B2 (en) * 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
US20080095918A1 (en) * 2006-06-14 2008-04-24 Kleiner Lothar W Coating construct with enhanced interfacial compatibility
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8679573B2 (en) * 2006-06-28 2014-03-25 Advanced Cardiovascular Systems, Inc. Stent coating method and apparatus
US8388573B1 (en) 2006-06-28 2013-03-05 Abbott Cardiovascular Systems Inc. Local delivery with a balloon covered by a cage
US8956640B2 (en) * 2006-06-29 2015-02-17 Advanced Cardiovascular Systems, Inc. Block copolymers including a methoxyethyl methacrylate midblock
WO2008002778A2 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
US20080008736A1 (en) * 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
US8016879B2 (en) * 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
US20080091262A1 (en) * 2006-10-17 2008-04-17 Gale David C Drug delivery after biodegradation of the stent scaffolding
CN100465209C (zh) * 2006-08-17 2009-03-04 同济大学 用于形状记忆管腔内支架的可降解高分子材料的制备方法
JP2010503469A (ja) 2006-09-14 2010-02-04 ボストン サイエンティフィック リミテッド 薬物溶出性皮膜を有する医療デバイス
US20080069858A1 (en) * 2006-09-20 2008-03-20 Boston Scientific Scimed, Inc. Medical devices having biodegradable polymeric regions with overlying hard, thin layers
US8636767B2 (en) * 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
CN102836023B (zh) 2006-10-18 2015-12-02 印斯拜尔Md有限公司 编织的支架套
EP1913960A1 (en) * 2006-10-19 2008-04-23 Albert Schömig Coated implant
EP1916006A1 (en) * 2006-10-19 2008-04-30 Albert Schömig Implant coated with a wax or a resin
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US20080294236A1 (en) * 2007-05-23 2008-11-27 Boston Scientific Scimed, Inc. Endoprosthesis with Select Ceramic and Polymer Coatings
WO2008062414A2 (en) 2006-11-22 2008-05-29 Inspiremd Ltd. Optimized stent jacket
WO2008088537A2 (en) * 2006-12-20 2008-07-24 Boston Scientific Limited Stent with a coating for delivering a therapeutic agent
US8221496B2 (en) * 2007-02-01 2012-07-17 Cordis Corporation Antithrombotic and anti-restenotic drug eluting stent
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
NZ580469A (en) * 2007-04-17 2012-05-25 Micell Technologies Inc Coronary stents having biodegradable layers
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US8084077B2 (en) * 2007-05-25 2011-12-27 Abbott Laboratories One-step phosphorylcholine-linked polymer coating and drug loading of stent
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US20100070020A1 (en) 2008-06-11 2010-03-18 Nanovasc, Inc. Implantable Medical Device
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
DE102007034364A1 (de) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Degradierbarer Metallstent mit wirkstoffhaltiger Beschichtung
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
WO2009020520A1 (en) 2007-08-03 2009-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US20090041845A1 (en) * 2007-08-08 2009-02-12 Lothar Walter Kleiner Implantable medical devices having thin absorbable coatings
US20090043380A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US20090043330A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Embolic protection devices and methods
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
US8556880B2 (en) * 2007-09-06 2013-10-15 Boston Scientific Scimed, Inc. Methods and devices for local therapeutic agent delivery to heart valves
US8100855B2 (en) 2007-09-17 2012-01-24 Abbott Cardiovascular Systems, Inc. Methods and devices for eluting agents to a vessel
US20090076584A1 (en) * 2007-09-19 2009-03-19 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US8142490B2 (en) * 2007-10-24 2012-03-27 Cordis Corporation Stent segments axially connected by thin film
US20090112239A1 (en) * 2007-10-31 2009-04-30 Specialized Vascular Technologies, Inc. Sticky dilatation balloon and methods of using
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US20090118812A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090118821A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with porous reservoir and non-polymer diffusion layer
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
CN101918051B (zh) 2007-11-14 2013-08-21 生物传感器国际集团有限公司 自动化涂覆设备和方法
MX2010006237A (es) 2007-12-07 2010-12-21 Vertex Pharma Formas solidas de 1-etil-3-(5-(5-fluoropiridin-3-il)-7-(pirimidin- 2-il)-1h-benzo[d]imidazol-2-il)urea.
CA2709901C (en) 2007-12-18 2022-05-10 Intersect Ent, Inc. Self-expanding devices and methods therefor
US20090186068A1 (en) * 2008-01-18 2009-07-23 Chameleon Scientific Corporation Atomic plasma deposited coatings for drug release
US20090196900A1 (en) * 2008-02-01 2009-08-06 Medtronic Vascular, Inc. Use of Phosphodiesterase Inhibitor as a Component of Implantable Medical Devices
US9603980B2 (en) * 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US8377116B2 (en) * 2008-03-20 2013-02-19 Abbott Cardiovascular Systems Inc. Implantable medical device coatings with improved mechanical stability
US11083579B2 (en) 2008-04-16 2021-08-10 Heart Repair Technologies, Inc. Transvalvular intraanular band and chordae cutting for ischemic and dilated cardiomyopathy
US20100121435A1 (en) 2008-04-16 2010-05-13 Cardiovascular Technologies, Llc Percutaneous transvalvular intrannular band for mitral valve repair
US10456259B2 (en) 2008-04-16 2019-10-29 Heart Repair Technologies, Inc. Transvalvular intraannular band for mitral valve repair
US11013599B2 (en) 2008-04-16 2021-05-25 Heart Repair Technologies, Inc. Percutaneous transvalvular intraannular band for mitral valve repair
US20100121437A1 (en) 2008-04-16 2010-05-13 Cardiovascular Technologies, Llc Transvalvular intraannular band and chordae cutting for ischemic and dilated cardiomyopathy
US20090285873A1 (en) * 2008-04-18 2009-11-19 Abbott Cardiovascular Systems Inc. Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide)
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
WO2009131911A2 (en) 2008-04-22 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
WO2009132176A2 (en) 2008-04-24 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
WO2009135125A2 (en) 2008-05-01 2009-11-05 Bayer Schering Pharma Ag Catheter balloon drug adherence techniques and methods
US8986728B2 (en) * 2008-05-30 2015-03-24 Abbott Cardiovascular Systems Inc. Soluble implantable device comprising polyelectrolyte with hydrophobic counterions
EP2303026B1 (en) 2008-06-17 2020-09-09 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
EP2303350A2 (en) 2008-06-18 2011-04-06 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8206635B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8206636B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8562669B2 (en) * 2008-06-26 2013-10-22 Abbott Cardiovascular Systems Inc. Methods of application of coatings composed of hydrophobic, high glass transition polymers with tunable drug release rates
CA2732355A1 (en) 2008-08-01 2010-02-04 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
AU2009296415B2 (en) 2008-09-25 2015-11-19 Advanced Bifurcation Systems Inc. Partially crimped stent
US8500687B2 (en) 2008-09-25 2013-08-06 Abbott Cardiovascular Systems Inc. Stent delivery system having a fibrous matrix covering with improved stent retention
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8828071B2 (en) 2008-09-25 2014-09-09 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
GB0819296D0 (en) * 2008-10-21 2008-11-26 Smith & Nephew Coating II
US20100119578A1 (en) * 2008-11-07 2010-05-13 Specialized Vascular Technologies, Inc. Extracellular matrix modulating coatings for medical devices
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2752544A1 (en) 2009-02-13 2010-08-19 Vertex Pharmaceuticals Incorporated Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
WO2010111232A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
MX2011010409A (es) * 2009-04-03 2012-01-20 Ashland Licensing & Intellectu Adhesivo acrilico sensible a la presion curable con radiacion ultravioleta.
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
EP2429624B1 (en) 2009-05-15 2014-04-02 Intersect ENT, Inc. A combination of an expandable device and a delivery device.
CA3186201A1 (en) * 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
WO2011040218A1 (ja) * 2009-09-30 2011-04-07 テルモ株式会社 ステント
WO2011044533A2 (en) 2009-10-09 2011-04-14 Specialized Vascular Technologies, Inc. Coating system and method for drug elution management
EP2338534A2 (de) * 2009-12-21 2011-06-29 Biotronik VI Patent AG Medizinisches Implantat, Beschichtungsverfahren sowie Implantationsverfahren
WO2011119884A1 (en) 2010-03-24 2011-09-29 Advanced Bifurcation Systems, Inc System and methods for treating a bifurcation
AU2011232361B2 (en) 2010-03-24 2015-05-28 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
CN103037815B (zh) 2010-03-24 2015-05-13 高级分支系统股份有限公司 通过临时张开侧分支来处理分叉部的方法和系统
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
WO2011126708A1 (en) 2010-04-06 2011-10-13 Boston Scientific Scimed, Inc. Endoprosthesis
DE102010018541A1 (de) * 2010-04-28 2011-11-03 Acandis Gmbh & Co. Kg Verfahren zur Herstellung einer medizinischen Vorrichtung
US20130032967A1 (en) * 2010-05-07 2013-02-07 Abbott Cardiovascular Systems Inc. Cold ethylene oxide sterilization of a biodegradable polymeric stent
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
ES2753529T3 (es) * 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
JP6120775B2 (ja) 2011-01-14 2017-04-26 スペロ トリネム, インコーポレイテッド ジャイレース阻害剤である(r)−1−エチル−3−[6−フルオロ−5−[2−(1−ヒドロキシ−1−メチル−エチル)ピリミジン−5−イル]−7−(テトラヒドロフラン−2−イル)−1h−ベンゾイミダゾール−2−イル]尿素の固体形態
CN103443096B (zh) 2011-01-14 2016-06-29 沃泰克斯药物股份有限公司 促旋酶和拓扑异构酶iv抑制剂
EP2670756B1 (en) 2011-02-04 2017-06-21 Synthon BV Process for making everolimus
EP2672932B1 (en) 2011-02-08 2018-09-19 Advanced Bifurcation Systems, Inc. System for treating a bifurcation with a fully crimped stent
CA2826760A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
US9187953B2 (en) 2011-03-23 2015-11-17 Rytec Corporation Side column configuration for overhead roll-up door assemblies
WO2012142319A1 (en) * 2011-04-13 2012-10-18 Micell Technologies, Inc. Stents having controlled elution
EP2721026B1 (en) 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
CN102389585B (zh) * 2011-07-07 2014-04-23 中山大学 一种在生物医用材料表面负载活性分子的方法
CA2842460C (en) 2011-07-20 2019-08-20 Brigham Young University Hydrophobic ceragenin compounds and devices incorporating same
US8932614B2 (en) 2011-08-25 2015-01-13 Paul B. Savage Incorporation of particulate ceragenins in polymers
RU2652308C2 (ru) 2011-09-13 2018-04-25 Брайем Янг Юниверсити Способы и продукты для заживления ран тканей
CA2852989C (en) 2011-09-13 2021-06-29 Brigham Young University Compositions for treating bone diseases and broken bones
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
CN104379120A (zh) 2011-12-21 2015-02-25 布莱阿姆青年大学 口腔护理组合物
US9220759B2 (en) 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
WO2014010759A1 (ko) * 2012-07-10 2014-01-16 주식회사 엠아이텍 인체에 삽입되는 루멘을 가진 원통형의 구조물
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
AU2013299425A1 (en) * 2012-08-10 2015-03-19 Altura Medical, Inc. Stent delivery systems and associated methods
CN102784418B (zh) * 2012-08-10 2014-04-16 中国医学科学院生物医学工程研究所 可程序性释放的生物药物纳米微孔血管支架及其制备方法与用途
ES2654189T3 (es) * 2012-09-12 2018-02-12 Boston Scientific Scimed, Inc. Revestimiento adhesivo anti-migración para stent
US9314472B2 (en) 2012-10-17 2016-04-19 Brigham Young University Treatment and prevention of mastitis
EP2737894A1 (en) 2012-12-03 2014-06-04 Debiotech S.A. Smart coating for implantable devices
JP6294352B2 (ja) 2013-01-07 2018-03-14 ブリガム・ヤング・ユニバーシティBrigham Young University 細胞増殖を減少させ、ある特定の疾患を治療する方法
CN105188831B (zh) 2013-03-14 2021-01-01 因特尔赛克特耳鼻喉公司 用于治疗鼻窦病状的系统、装置以及方法
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
KR102282183B1 (ko) 2013-03-15 2021-07-26 브라이엄 영 유니버시티 염증, 자가면역 장애 및 통증의 치료 방법
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
WO2015020527A1 (en) 2013-08-09 2015-02-12 Maastricht University Biodegradable radiopaque stents and other implants
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
EP3424920B1 (en) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
US9459193B2 (en) * 2013-12-18 2016-10-04 Abbott Cardiovascular Systems Inc. Stent holder having a reduced profile
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9622891B2 (en) 2014-04-17 2017-04-18 Abbott Cardiovascular Systems Inc. Coatings for braided medical devices and methods of forming same
EP3934353A1 (en) 2014-04-21 2022-01-05 Kabushiki Kaisha Toshiba Base stations and wireless communication methods
WO2015163336A1 (ja) 2014-04-21 2015-10-29 株式会社 東芝 無線通信用集積回路
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
EP3166950A1 (en) * 2014-08-04 2017-05-17 Cipla Limited Process for the synthesis of everolimus and intermediates thereof
DE102014111117B4 (de) * 2014-08-05 2017-11-16 Acandis Gmbh & Co. Kg Medizinische Vorrichtung zur Behandlung von neurovaskulären Erkrankungen, System und Set mit einer derartigen Vorrichtung sowie Herstellungsverfahren
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
CN104478898A (zh) * 2014-11-18 2015-04-01 连云港恒运医药科技有限公司 依维莫司及其中间体的制备方法
WO2016114216A1 (ja) * 2015-01-13 2016-07-21 テルモ株式会社 生分解性ステント
WO2016172553A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
CN108024825B (zh) * 2015-09-25 2021-07-30 斯贝洛克斯公司 鼻植入物和系统及使用方法
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US20180161185A1 (en) * 2016-12-14 2018-06-14 eLum Technologies, Inc. Electrospun stents, flow diverters, and occlusion devices and methods of making the same
WO2018114992A1 (en) * 2016-12-22 2018-06-28 Biotronik Ag Drug releasing coatings for medical devices and methods of making same
WO2018119304A1 (en) 2016-12-22 2018-06-28 Heart Repair Technologies, Inc. Percutaneous delivery systems for anchoring an implant in a cardiac valve annulus
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
EP3740167A4 (en) * 2018-01-16 2021-11-03 Sintra Medical Llc STENTS WITH INCREASED FLEXIBILITY
US11224512B2 (en) * 2018-03-21 2022-01-18 Edwards Lifesciences Corporation Coronary artery check valve
US11179255B2 (en) 2018-03-29 2021-11-23 Sahajanand Medical Technologies Limited Medical devices
RU2686747C1 (ru) * 2018-11-08 2019-04-30 Федеральное государственное бюджетное учреждение науки Институт металлургии и материаловедения им. А.А. Байкова Российской академии наук (ИМЕТ РАН) Способ получения биодеградируемого полимерного покрытия на основе полилактида на проволоке TiNbTaZr
US11541152B2 (en) 2018-11-14 2023-01-03 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
CN116869715B (zh) * 2023-07-10 2024-02-09 上海心玮医疗科技股份有限公司 一种抗凝药物洗脱支架

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US517698A (en) 1894-04-03 Druggist s weighing-scale
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5527337A (en) 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
US5059211A (en) 1987-06-25 1991-10-22 Duke University Absorbable vascular stent
US5176908A (en) 1988-12-19 1993-01-05 American Cyanamid Company Method for the treatment of endotoxic shock in mammal
US4990155A (en) 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
CA2049973C (en) 1990-02-28 2002-12-24 Rodney G. Wolff Intralumenal drug eluting prosthesis
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5258020A (en) * 1990-09-14 1993-11-02 Michael Froix Method of using expandable polymeric stent with memory
WO1992015342A1 (en) 1991-03-08 1992-09-17 Keiji Igaki Stent for vessel, structure of holding said stent, and device for mounting said stent
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US6013853A (en) 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5540712A (en) 1992-05-01 1996-07-30 Nitinol Medical Technologies, Inc. Stent and method and apparatus for forming and delivering the same
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5443458A (en) 1992-12-22 1995-08-22 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method of manufacture
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE4303181A1 (de) 1993-02-04 1994-08-11 Angiomed Ag Implantierbarer Katheter
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5824048A (en) 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
PL314238A1 (en) * 1993-12-17 1996-09-02 Sandoz Ltd Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5649977A (en) * 1994-09-22 1997-07-22 Advanced Cardiovascular Systems, Inc. Metal reinforced polymer stent
US5733327A (en) 1994-10-17 1998-03-31 Igaki; Keiji Stent for liberating drug
US5707385A (en) 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5565772A (en) 1994-11-30 1996-10-15 Eastman Kodak Company High sensitivity magnetic viewer using anhysteretic transfer for viewing weak magnetic patterns
US5869127A (en) 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6179817B1 (en) 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
AU729119B2 (en) * 1996-04-08 2001-01-25 Iowa-India Investments Company Limited Multiple interconnected stents and method of coating stents
ATE340586T1 (de) 1996-07-30 2006-10-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6174329B1 (en) * 1996-08-22 2001-01-16 Advanced Cardiovascular Systems, Inc. Protective coating for a stent with intermediate radiopaque coating
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
WO1998036784A1 (en) 1997-02-20 1998-08-27 Cook Incorporated Coated implantable medical device
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
CA2294917C (en) * 1997-06-18 2009-01-06 Boston Scientific Corporation Polycarbonate-polyurethane dispersions for thrombo-resistant coatings
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
AU741328B2 (en) * 1997-08-08 2001-11-29 Sunscope International, Inc. Microporous stent and implantation device
US6159488A (en) 1997-08-14 2000-12-12 Agricultural Research Org. Ministry Of Agriculture (Gov.) Intracoronary stents containing quinazolinone derivatives
US6042606A (en) 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6129755A (en) 1998-01-09 2000-10-10 Nitinol Development Corporation Intravascular stent having an improved strut configuration
US6190406B1 (en) 1998-01-09 2001-02-20 Nitinal Development Corporation Intravascular stent having tapered struts
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
EP1555036B1 (en) 1998-04-27 2010-05-05 Surmodics Inc. Bioactive agent release coating
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US20020038146A1 (en) * 1998-07-29 2002-03-28 Ulf Harry Expandable stent with relief cuts for carrying medicines and other materials
WO2000010622A1 (en) 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
AU5405399A (en) 1998-09-14 2000-04-03 Vesifact Ag Utilization of nanocells in final culture medium products
WO2000045763A1 (en) 1999-02-02 2000-08-10 The Procter & Gamble Company Elastic laminate including spunbonded nonwoven of polypropylene/polyethylene copolymer and disposable article using the same
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6607598B2 (en) * 1999-04-19 2003-08-19 Scimed Life Systems, Inc. Device for protecting medical devices during a coating process
WO2001014387A1 (en) * 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6713119B2 (en) 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
IL133312A (en) 1999-12-05 2006-09-05 Orbotech Ltd Method for testing a printed circuit
WO2001045644A2 (en) * 1999-12-23 2001-06-28 Combe International Ltd. Dental adhesive device and method for producing same
ATE475418T1 (de) * 2000-01-14 2010-08-15 Univ Pennsylvania O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
US7220276B1 (en) * 2000-03-06 2007-05-22 Surmodics, Inc. Endovascular graft coatings
AU2001255438B2 (en) * 2000-05-16 2005-03-24 Ortho-Mcneil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6569191B1 (en) * 2000-07-27 2003-05-27 Bionx Implants, Inc. Self-expanding stent with enhanced radial expansion and shape memory
DE10046448A1 (de) * 2000-09-18 2002-03-28 Daimler Chrysler Ag Verfahren zur Bestimmung des Momentes an der Kurbelwelle einer Brennkraftmaschine
WO2002026162A2 (en) * 2000-09-26 2002-04-04 Advanced Cardiovascular Systems, Inc. A method of loading a substance onto an implantable device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US6863685B2 (en) 2001-03-29 2005-03-08 Cordis Corporation Radiopacity intraluminal medical device
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
DE60112318D1 (de) * 2000-10-16 2005-09-01 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
CA2458828A1 (en) * 2001-09-24 2003-05-01 James J. Barry Optimized dosing for drug coated stents
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US7179283B2 (en) 2001-11-02 2007-02-20 Scimed Life Systems, Inc. Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US6743463B2 (en) * 2002-03-28 2004-06-01 Scimed Life Systems, Inc. Method for spray-coating a medical device having a tubular wall such as a stent
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7294145B2 (en) * 2004-02-26 2007-11-13 Boston Scientific Scimed, Inc. Stent with differently coated inside and outside surfaces

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
CN101264351B (zh) * 2008-04-07 2011-08-24 易生科技(北京)有限公司 复合涂层心血管药物洗脱支架及其制备方法
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
CN102481195B (zh) * 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
CN102481195A (zh) * 2009-04-01 2012-05-30 米歇尔技术公司 涂覆支架
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN104203959B (zh) * 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
CN104203959A (zh) * 2012-06-08 2014-12-10 百多力股份公司 雷帕霉素40-o-环状烃酯、组合物和方法
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
CN104592254A (zh) * 2015-02-08 2015-05-06 福建省微生物研究所 依维莫司的合成方法
CN105566348A (zh) * 2015-12-31 2016-05-11 哈药集团技术中心 一种依维莫司的制备方法
CN108720971A (zh) * 2018-01-28 2018-11-02 杭州市第人民医院 一种可控抗菌气管支架

Also Published As

Publication number Publication date
AU2009201655B2 (en) 2011-03-24
AU2003231757A1 (en) 2003-11-10
JP2012205920A (ja) 2012-10-25
JP2014087714A (ja) 2014-05-15
JP5461624B2 (ja) 2014-04-02
WO2003090818A3 (en) 2003-12-04
JP2013121509A (ja) 2013-06-20
CN1735402A (zh) 2006-02-15
CN1649551B (zh) 2010-08-11
JP2005523332A (ja) 2005-08-04
AU2003231759B2 (en) 2009-02-05
HK1150229A1 (en) 2011-11-11
US7727275B2 (en) 2010-06-01
WO2003090684A2 (en) 2003-11-06
EP2417943B1 (en) 2014-08-27
AU2003231757B2 (en) 2009-07-09
WO2003090684A8 (en) 2004-12-16
US8308795B2 (en) 2012-11-13
AU2009201655A1 (en) 2009-05-21
JP2008279278A (ja) 2008-11-20
EP1505930B1 (en) 2014-07-30
ES2514391T3 (es) 2014-10-28
EP1505930A2 (en) 2005-02-16
JP2012091032A (ja) 2012-05-17
EP2113230A2 (en) 2009-11-04
EP2578186A2 (en) 2013-04-10
EP2578186B1 (en) 2014-07-23
WO2003090684A3 (en) 2004-02-26
JP5827355B2 (ja) 2015-12-02
US20100312328A1 (en) 2010-12-09
US20050038505A1 (en) 2005-02-17
EP1518517B1 (en) 2009-12-09
US20030225450A1 (en) 2003-12-04
ES2335406T3 (es) 2010-03-26
EP2316377A1 (en) 2011-05-04
US20130035754A1 (en) 2013-02-07
US20140200654A1 (en) 2014-07-17
US6939376B2 (en) 2005-09-06
JP2009011847A (ja) 2009-01-22
EP2578186A3 (en) 2013-05-22
JP4315817B2 (ja) 2009-08-19
ES2523870T3 (es) 2014-12-02
US20030125800A1 (en) 2003-07-03
HK1156494A1 (zh) 2012-06-15
HK1177882A1 (zh) 2013-08-30
EP1518517A3 (en) 2005-12-14
ES2522277T3 (es) 2014-11-14
EP1505930A4 (en) 2006-05-03
JP5726777B2 (ja) 2015-06-03
EP2113230A3 (en) 2010-06-23
CN101862233B (zh) 2012-09-05
WO2003090818A2 (en) 2003-11-06
AU2003231759A1 (en) 2003-11-10
ATE451075T1 (de) 2009-12-15
JP5113667B2 (ja) 2013-01-09
CN101862233A (zh) 2010-10-20
WO2003090684B1 (en) 2004-05-13
EP2316377B1 (en) 2014-11-05
JP2005523119A (ja) 2005-08-04
EP2417943A1 (en) 2012-02-15
US8715341B2 (en) 2014-05-06
DE60330455D1 (de) 2010-01-21
EP1518517A2 (en) 2005-03-30

Similar Documents

Publication Publication Date Title
CN1649551A (zh) 药物释放型血管内支架和治疗再狭窄的方法
CN1684641A (zh) 用于递送丝裂霉素通过洗脱生物相容可移植医疗器件的装置和方法
CN1964748A (zh) 用于生物活性剂的涂料组合物
JP5209726B2 (ja) 三酸化二ヒ素薬剤溶出ステント
JP5153340B2 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
CN1635861A (zh) 含有药物的聚合物包覆的支架组件
CN101795719B (zh) 药物缓释性支架
CN102210616B (zh) 完全可降解聚合物药物洗脱支架及其制备方法
CN1520297A (zh) 包含复合药物(codrugs)的缓释药物传递系统
JP2008526371A (ja) ブレンドを含む生分解性コーティング組成物
JP2008526322A (ja) 多層を含む生分解性コーティング組成物
CN106693078A (zh) 一种载药层层自组装涂层的制备方法
TW200418538A (en) Medical devices incorporating deuterated rapamycin for controlled delivery thereof
JP2007516757A (ja) 医薬組成物
CN1964750A (zh) 用于医疗用具的生物活性的涂料组合物
CN1764482A (zh) 血管支架
CN102091355A (zh) 一种复合涂层冠脉药物洗脱支架及其制备方法
JP2008253707A (ja) 薬剤溶出ステント
CN1950115A (zh) 用于生物相容性表面的方法和系统
CN1557507A (zh) 防再狭窄药物缓释型血管支架及其制备方法
CN101467921B (zh) 药物洗脱支架的生产方法
CN1878579A (zh) 制备药物洗脱医疗器械的方法和由该方法得到的医疗器械
CN1750855A (zh) 支架
CN101601617B (zh) 一种颅内紫杉醇药物释放支架及其制备方法
CN1565663A (zh) 药物改性心血管支架

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOSENSORS INTERNAT GROUP LTD

Free format text: FORMER OWNER: SOLAR BIO-MEDICAL CO.,LTD

Effective date: 20090410

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090410

Address after: Bermuda (UK) Hamilton

Applicant after: BIOSENSORS INTERNATIONAL Group

Address before: Bermuda (UK) Hamilton

Applicant before: SUN BIOMEDICAL, Ltd.

C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: R.E. Bates

Inventor after: D.R. Savage

Inventor before: Schulze John E.

Inventor before: R.E. Bates

Inventor before: D.R. Savage

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100811